<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8549">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826228</url>
  </required_header>
  <id_info>
    <org_study_id>STU00003009</org_study_id>
    <nct_id>NCT00826228</nct_id>
  </id_info>
  <brief_title>Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)</brief_title>
  <official_title>Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas J. Schnitzer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rehabilitation Institute of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with spinal cord injury sustain significant loss of bone mass in their lower
      extremities (20-40% or more). This study evaluates the ability of PTH and weight-bearing,
      two interventions that build bone, to increase bone mass in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot project aims to evaluate PTH with weight-bearing in a group of individuals with
      chronic SCI and loss of bone mass in their lower extremities. A convenience sample of 12
      people with SCI will be enrolled into a 6 month study assessing the effects of a
      weight-bearing regime plus daily PTH (Forteo 20ug sc) on BMD and bone markers. Subjects will
      be evaluated at 3 and 6 months after initiating treatment with measurement of bone density
      as well as bone markers of formation and resorption. An optional extension to 12 months will
      be offered to all subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>BMD at Left Total Hip</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bone mineral density (gm/cm2) of the total hip region of interest on the left</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>P1NP</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>amino-terminal propeptide of type I collagen (P1NP)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Bone Loss</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>PTH/Weight-Bearing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriparatide</intervention_name>
    <description>teriparatide 20ug daily sc for 6 months</description>
    <arm_group_label>PTH/Weight-Bearing</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>weight-bearing</intervention_name>
    <description>device assisted walking</description>
    <arm_group_label>PTH/Weight-Bearing</arm_group_label>
    <other_name>exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years

          2. Complete SCI - total loss of motor function below level of lesion

          3. Capable of positioning to have DEXA performed

          4. Capable of undertaking the weight-bearing exercise regime

          5. Capable of reading and understanding informed consent document

          6. Able to self-administer PTH or have someone in the family who can do so

          7. T score &lt;-2.5 or Z score &lt;-1.5 on evaluation of total hip BMD

          8. No known endocrinopathies

          9. Normal TSH levels

         10. Normal 25-OH vitamin D levels

         11. Normal calcium levels

         12. Normal renal function (creatinine &lt;2.0mg/dl)

         13. Able to return for all follow-up visits

        Exclusion Criteria:

          1. Surgical or other intervention resulting in metal or anatomy precluding obtaining
             DEXA and/or MRI measurements

          2. Other medical conditions that in the opinion of the investigator would preclude the
             subject from completing the study

          3. History of malignancy

          4. History of radiation therapy

          5. Unable to self-administer PTH or have it administered

          6. Elevated liver function tests &gt;2x normal

          7. For males, significantly abnormal free testosterone levels

          8. Currently being prescribed anti-convulsants

          9. Currently being prescribed glucocorticoids, other than inhaled glucocorticoids

         10. Currently being prescribed any bone-active agents, including any bisphosphonate,
             raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or
             strontium-containing compounds.

         11. No previous history of bisphosphonate use

         12. No previous use of other bone-specific agents during past 2 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Schnitzer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rehabilitation Institute of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 3, 2013</lastchanged_date>
  <firstreceived_date>January 20, 2009</firstreceived_date>
  <firstreceived_results_date>April 17, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Thomas J. Schnitzer</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from outpatient clinic at rehab hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PTH/Weight-Bearing</title>
          <description>PTH 20ug/day plus assisted weight-bearing on a Lokomat</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PTH/Weight-Bearing</title>
          <description>PTH 20ug/day plus assisted weight-bearing of one hour 3x/week</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34.0" spread="7.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BMD at Left Total Hip</title>
        <description>Bone mineral density (gm/cm2) of the total hip region of interest on the left</description>
        <time_frame>Baseline to 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>PTH/Weight-Bearing</title>
            <description>PTH 20ug/day plus assisted weight-bearing of one hour 3x/week</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>BMD at Left Total Hip</title>
            <description>Bone mineral density (gm/cm2) of the total hip region of interest on the left</description>
            <units>% change in BMD (gm/cm2) from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.02" spread="2.21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P1NP</title>
        <description>amino-terminal propeptide of type I collagen (P1NP)</description>
        <time_frame>Baseline to 6 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Only 8 of the total 12 participants enrolled had serum available for testing</population>
        <group_list>
          <group group_id="O1">
            <title>PTH/Weight-Bearing</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>P1NP</title>
            <description>amino-terminal propeptide of type I collagen (P1NP)</description>
            <units>% change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61.4" spread="99.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PTH/Weight-Bearing</title>
          <description>PTH 20ug/day plus assisted weight-bearing of one hour 3x/week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects analyzed with considerable between-subject variability.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas J Schnitzer</name_or_title>
      <organization>Northwestern University Feinberg School of Medicine</organization>
      <phone>3125032315</phone>
      <email>tjs@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
